NFKB1 and Alzheimer disease: Given the central role of the TLR4/NF-κB pathway in AD progression and the strong link between UFMylation and this signaling axis, targeting UFMylation alongside TLR4 and NF-κB signaling pathways may present novel therapeutic strategies to mitigate neuroinflammation and its detrimental effects in AD.